The European Medicines Agency (EMA) has ordered the withdrawal of all levamisole-based medicines due to the risk of leukoencephalopathy, a rare but potentially serious neurological condition. Following a comprehensive safety review, sales of these medicines have been suspended across the European Union.
Why the EMA Ordered the Withdrawal of Levamisole
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), which is responsible for monitoring the safety of medicines in the European Union, has recommended the withdrawal of all medicines containing levamisole.
After reviewing all available safety data, the committee concluded that the benefits of levamisole no longer outweigh its potential risks. Under European pharmaceutical regulations, a medicine may be suspended or withdrawn when its risks are considered greater than its therapeutic benefits.
The Risk of Leukoencephalopathy
The primary reason for the withdrawal is the risk of developing leukoencephalopathy, a condition that affects the brain’s white matter.
White matter consists of nerve fibers covered by myelin, a protective sheath that allows nerve signals to travel efficiently throughout the brain and nervous system. Damage to these structures can impair important neurological functions.
According to the EMA, levamisole-associated leukoencephalopathy is:
- Rare
- Potentially serious
- Possible even after a single dose of the medication
Symptoms may develop within 24 hours of taking the drug or may appear several months after treatment.
What Was Levamisole Used For?
Levamisole has primarily been used to treat mild parasitic worm infections.
Because these conditions are generally not life-threatening, and considering the identified neurological risks, the EMA concluded that the overall benefit-risk balance is no longer favorable.
In its official statement, the Agency confirmed that all medicines containing levamisole will be withdrawn from the market throughout the European Union.
List of Affected Medicines
The EMA has published an updated list of levamisole-containing medicines that will no longer be available in EU member states. National health authorities will oversee the implementation of the withdrawal.
Patients who are currently taking a medicine containing levamisole are advised to consult their doctor or pharmacist for guidance and to discuss appropriate alternative treatments.
